The History of Biomarkers How Far Have We Come?

被引:1
|
作者
Lachmann, Gunnar [1 ,2 ,3 ,4 ,5 ]
Reinhart, Konrad [1 ,2 ,3 ,4 ,5 ,6 ]
机构
[1] Charite Univ Med Berlin, CVK, Dept Anesthesiol & Operat Intens Care Med CCM, Augustenburger Pl 1, D-13353 Berlin, Germany
[2] Free Univ Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany
[3] Humboldt Univ, Augustenburger Pl 1, D-13353 Berlin, Germany
[4] Berlin Inst Hlth, Augustenburger Pl 1, D-13353 Berlin, Germany
[5] Berlin Inst Hlth, Anna Louisa Karsch Str 2, D-10178 Berlin, Germany
[6] Jena Univ Hosp, Carl Zeiss Str 12, D-07743 Jena, Germany
关键词
Sepsis; Biomarker; History; INTERNATIONAL CONSENSUS DEFINITIONS; LIPOPOLYSACCHARIDE-BINDING-PROTEIN; SEVERE SEPSIS; SEPTIC SHOCK; FRAGMENT AFELIMOMAB; PROCALCITONIN; INTERLEUKIN-6; DYSFUNCTION; NEUTROPHILS; EFFICACY;
D O I
10.1016/j.ccc.2019.08.001
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Sepsis is one of the oldest and most elusive syndromes in medicine that is still incompletely understood. Biomarkers may help to transform sepsis from a physiologic syndrome to a group of distinct biochemical disorders. This will help to differentiate between systemic inflammation of infectious and noninfectious origin and aid therapeutic decision making, hence improve the prognosis for patients, guide antimicrobial therapy, and foster the development of novel adjunctive sepsis therapies. To reach this goal requires increased systematic investigation that includes twenty-first century scientific approaches and technologies and appropriate clinical evaluation.
引用
下载
收藏
页码:1 / +
页数:11
相关论文
共 50 条
  • [21] Autoantibodies in Atrial Fibrillation: Actors, Biomarkers or Bystanders? How Far Have We Come?
    Fu, Michael
    CARDIOLOGY, 2009, 112 (03) : 178 - 179
  • [22] Early diagnostic protein biomarkers for breast cancer: how far have we come?
    Winden, Annemieke W. J. Opstal-van
    Vermeulen, Roel C. H.
    Peeters, Petra H. M.
    Beijnen, Jos H.
    van Gils, Carla H.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 1 - 12
  • [23] Early diagnostic protein biomarkers for breast cancer: how far have we come?
    Annemieke W. J. Opstal-van Winden
    Roel C. H. Vermeulen
    Petra H. M. Peeters
    Jos H. Beijnen
    Carla H. van Gils
    Breast Cancer Research and Treatment, 2012, 134 : 1 - 12
  • [24] HOW FAR HAVE WE COME - WHERE ARE WE GOING
    HOOPER, JF
    JOURNAL OF RANGE MANAGEMENT, 1968, 21 (03): : 186 - &
  • [25] Milestones in Heart Failure: How Far We Have Come and How Far We Have Left to Go
    Gajjela, Harini
    Kela, Iljena
    Kakarala, Chandra L.
    Hassan, Mohammad
    Belavadi, Rishab
    Gudigopuram, Sri Vallabh Reddy
    Raguthu, Ciri C.
    Modi, Srimy
    Sange, Ibrahim
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (12)
  • [26] Electronic health records: How far have we come? How far do we have to go?
    Waegemann, CP
    TOWARD AN ELECTRONIC HEALTH RECORD EUROPE '97 - CONFERENCE ON THE CREATION OF A EUROPEAN ELECTRONIC HEALTH RECORD, CONFERENCE PROCEEDINGS, 1997, : 8 - 10
  • [27] DIVERSITY AND INCLUSION: HOW FAR HAVE WE COME? HOW FAR CAN WE GO?
    Pennington, Greg
    CONSULTING PSYCHOLOGY JOURNAL-PRACTICE AND RESEARCH, 2020, 72 (04) : 324 - 331
  • [28] Tracheobronchomalacia treatment: how far have we come?
    Lopez-Padilla, Daniel
    Garcia-Lujan, Ricardo
    Puente Maestu, Luis
    de Miguel Poch, Eduardo
    JOURNAL OF THORACIC DISEASE, 2016, 8 (12) : 3490 - 3493
  • [29] Cardiopulmonary Resuscitation How Far Have We Come?
    Whitcomb, John J.
    Blackman, Virginia Schmied
    DIMENSIONS OF CRITICAL CARE NURSING, 2007, 26 (01) : 1 - 6
  • [30] Immunotherapy in myeloma: how far have we come?
    Franssen, Laurens E.
    Mutis, Tuna
    Lokhorst, Henk M.
    van de Donk, Niels W. C. J.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10 : 1 - 19